Biomark Diagnostics (Biomark Diagnostics) Total Liabilities : $1.42 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics Total Liabilities?

Biomark Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 was $1.42 Mil.

Biomark Diagnostics's quarterly Total Liabilities declined from Jun. 2023 ($1.40 Mil) to Sep. 2023 ($1.32 Mil) but then increased from Sep. 2023 ($1.32 Mil) to Dec. 2023 ($1.42 Mil).

Biomark Diagnostics's annual Total Liabilities increased from Mar. 2021 ($0.82 Mil) to Mar. 2022 ($1.66 Mil) but then declined from Mar. 2022 ($1.66 Mil) to Mar. 2023 ($1.38 Mil).

Biomark Diagnostics Total Liabilities Historical Data

The historical data trend for Biomark Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Total Liabilities Chart

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

0.94

0.77

0.82

1.66

1.38

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1.29	1.38	1.40	1.32	1.42

Biomark Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biomark Diagnostics's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.216	+	(0.159	+	2.7755575615629E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.38

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	0.535	-	-0.84
	=	1.38

Biomark Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.016	+	(0.408	+	-0.00099999999999995
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.42

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1.006	-	-0.417
	=	1.42

Biomark Diagnostics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines